Lecap Asset Management Ltd. Boosts Holdings in Hologic, Inc. (NASDAQ:HOLX)

Lecap Asset Management Ltd. raised its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 30.0% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 65,592 shares of the medical equipment provider's stock after buying an additional 15,131 shares during the quarter. Hologic comprises 0.9% of Lecap Asset Management Ltd.'s portfolio, making the stock its 3rd largest position. Lecap Asset Management Ltd.'s holdings in Hologic were worth $4,052,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. Principal Financial Group Inc. grew its holdings in Hologic by 0.6% in the 4th quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock worth $19,547,000 after buying an additional 1,606 shares in the last quarter. Farther Finance Advisors LLC lifted its position in shares of Hologic by 22.3% in the 1st quarter. Farther Finance Advisors LLC now owns 1,835 shares of the medical equipment provider's stock valued at $113,000 after acquiring an additional 335 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Hologic by 116.6% in the first quarter. SG Americas Securities LLC now owns 9,609 shares of the medical equipment provider's stock valued at $594,000 after purchasing an additional 5,172 shares in the last quarter. Groupama Asset Managment boosted its position in Hologic by 63.4% during the 4th quarter. Groupama Asset Managment now owns 54,214 shares of the medical equipment provider's stock worth $3,918,000 after acquiring an additional 21,037 shares during the period. Finally, Proficio Capital Partners LLC acquired a new stake in shares of Hologic during the fourth quarter worth approximately $4,215,000. 94.73% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Martin D. Madaus purchased 5,445 shares of the business's stock in a transaction on Wednesday, May 7th. The shares were purchased at an average price of $55.24 per share, with a total value of $300,781.80. Following the completion of the purchase, the director now owns 5,445 shares in the company, valued at $300,781.80. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.88% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on HOLX shares. Raymond James Financial reaffirmed an "outperform" rating and issued a $71.00 target price (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Morgan Stanley decreased their price objective on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a report on Monday, May 5th. Wall Street Zen downgraded shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Evercore ISI reduced their price target on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a report on Friday, May 2nd. Finally, Stephens dropped their price objective on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research note on Tuesday, May 13th. Twelve research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $77.42.

Hologic Price Performance

NASDAQ:HOLX traded down $0.10 during mid-day trading on Friday, reaching $65.01. 3,320,131 shares of the company were exchanged, compared to its average volume of 2,371,550. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.67. The company has a fifty day moving average of $60.00 and a 200 day moving average of $64.06. The company has a quick ratio of 2.52, a current ratio of 3.24 and a debt-to-equity ratio of 0.54. The stock has a market cap of $14.49 billion, a PE ratio of 27.43, a PEG ratio of 2.39 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The company's revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.03 EPS. On average, research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.